News
Stay updated, follow our news
11 December 2025
Azafaros further strengthens its Board of Directors with appointment of biotech entrepreneur, Dr. Thierry Abribat
Read more
28 July 2025
Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively
Read more
9 June 2025
Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing
Read more
13 May 2025
Azafaros Secures € 132M in Oversubscribed Series B Financing to advance Phase 3 clinical programs of innovative therapies in lysosomal storage disorders
Read more
8 January 2025
Azafaros granted important regulatory designations and clearance by European authorities for global Phase 3 studies, to be initiated in 2025
Read more
19 November 2024
Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 2025
Read more
10 September 2024
Positive Niemann-Pick disease type C (NPC) and GM2 gangliosidosis data from nizubaglustat Phase 2 RAINBOW study conducted by Azafaros presented at major metabolic disease conference
Read more
16 July 2024
Azafaros announces positive topline Phase 2 study data with nizubaglustat in GM2 gangliosidosis and Niemann-Pick disease type C
Read more
2 April 2024
Azafaros announces promotion of Dr Anke Arnold-Tugulu to Chief Regulatory Officer
Read more
12 March 2024
Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients
Read more
23 January 2024
Azafaros to present data from PRONTO study in patients with GM1 and GM2 gangliosidoses at the 20th annual WORLDSymposium
Read more
11 December 2023
Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolled
Read more
8 July 2023
Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients
Read more
20 February 2023
Azafaros Receives Additional Regulatory Designations for AZ-3102 from FDA, EMA and MHRA
Read more
9 January 2023
Azafaros Strengthens Medical and Scientific Management Team Reflecting Clinical Progress
Read more
5 January 2023
BREAKING NEWS: Azafaros Receives FDA’s IND Clearance and Fast Track Designation
Read more
24 April 2022
Azafaros Announces FDA Grant of Orphan Drug Designation for AZ-3102 in the Treatment of Niemann-Pick Disease
Read more
14 February 2022
Azafaros Presents Positive Clinical and Preclinical Data Supporting Development of Lead Compound AZ-3102 in Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Conference
Read more
1 February 2022
Azafaros Receives FDA Orphan Drug Designation for AZ-3102 in GM2 Gangliosidosis
Read more
6 April 2021
Azafaros enters clinical stage with AZ-3102, an oral small molecule being developed for rare neurogenetic disorders
Read more
6 February 2020
Azafaros completes EUR 25 million Series A financing to advance rare metabolic disorders pipeline
Read more
23 June 2018